BIOA Investors Stunned By Liver Toxicity Claims

When BioAge labs announced it was pulling the plug on clinical trials of one of its drugs, investors then pulled the plug on BioAge Labs. Shareholders quickly dumped their shares and BioAge's stock price plunged 25% overnight. Some of those investors are now taking legal action against the Company.

BioAge was investigating a potential obesity treatment called azelaprag. It had completed Phase 1 trials. The Phase 2 trial, called STRIDE, was set to complete in late 2025. BioAge went public in September 2024. In its IPO papers, BioAge touted azelaprag, the success of the Phase 1 trials, and the ongoing STRIDE trials.

So investors were shocked in December 2024 when BioAge suddenly halted the STRIDE trial. The Company revealed some STRIDE participants were showed signs of liver toxicity. Analysts expressed surprise at the news, noting it is unusual that that liver toxicity had never appeared across any of the eight Phase 1 trials or other investigations BioAge conducted on the drug.

Investors rapidly sold off their shares and BioAge's stock price plummeted. Now, some of those investors are joining the lawsuit.